Novo Nordisk is eyeing domestic diabetes market

Published: 2007-10-22 06:56:00
Updated: 2007-10-22 06:56:00
Novo Nordisk Korea is intensifying heated marketing efforts on a new long-acting insulin analogue Levemir (insulin detemir) to strengthen its presence in local diabetes market.

Levemir is a long-acting basal insulin analog indicated for once- or twice-daily subcutaneous administration for the...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.